Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Up 15.4% in January

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 463,600 shares, an increase of 15.4% from the January 15th total of 401,900 shares. Based on an average daily trading volume, of 58,300 shares, the short-interest ratio is currently 8.0 days. Approximately 3.0% of the company’s stock are sold short.

Analyst Ratings Changes

A number of brokerages recently weighed in on AXDX. StockNews.com began coverage on shares of Accelerate Diagnostics in a research note on Thursday. They set a “hold” rating for the company. BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Insider Activity

In related news, Director John Patience bought 200,000 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the acquisition, the director now owns 653,224 shares in the company, valued at approximately $1,025,561.68. This represents a 44.13 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 43.60% of the company’s stock.

Institutional Trading of Accelerate Diagnostics

Hedge funds have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd acquired a new stake in shares of Accelerate Diagnostics in the 3rd quarter worth $34,000. Jane Street Group LLC acquired a new stake in shares of Accelerate Diagnostics in the 4th quarter worth $27,000. Renaissance Technologies LLC lifted its stake in shares of Accelerate Diagnostics by 160.6% in the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after acquiring an additional 65,984 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Accelerate Diagnostics by 6.9% in the 4th quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock worth $163,000 after acquiring an additional 8,777 shares during the period. Institutional investors and hedge funds own 17.14% of the company’s stock.

Accelerate Diagnostics Price Performance

Shares of NASDAQ:AXDX opened at $1.18 on Monday. The stock has a market cap of $29.55 million, a P/E ratio of -0.41 and a beta of 0.61. The firm has a fifty day moving average price of $1.21 and a 200 day moving average price of $1.54. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $2.09.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.